Watch out Tesaro, As­traZeneca and Mer­ck get FDA OK for broad use of Lyn­parza

As­traZeneca and its new Big Phar­ma part­ner Mer­ck have picked up the FDA’s ap­proval for the broad use of Lyn­parza, which will put it di­rect­ly in the mar­ket­ing path be­ing blazed by Tesaro.

Like Tesaro’s Ze­ju­la, Lyn­parza (ola­parib) can now be used as a main­te­nance ther­a­py for re­cur­rent ovar­i­an can­cer, re­gard­less of BR­CA mu­ta­tion sta­tus. And reg­u­la­tors al­so OK’d an eas­i­er dos­ing reg­i­men, with two tablets twice a day in­stead of eight cap­sules dai­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER